Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Catalent

Recent acquisitions drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
3Q Revenues: $627.9 million (+18%)
3Q Earnings: $19.0 million (-27%)
YTD Revenues: $1.8 billion (+18%)
YTD Earnings: $0.9 million (earnings were $48 million YTD17)
Comments: Revenue from the Softgel Technologies segment was $228.5 million in the quarter, up 9% primarily attributable to the February 2017 Accucaps acquisition. Revenue from the Drug Delivery Solutions segment was $313.6 million, an increase of 34%. This growth was primarily attributable to the Cook Pharmica acquisition which contributed 26 percentage points. Clinical Supply Services segment revenue was $104.4 million, up 7% due to higher volume related to storage and distribution services, partially offset by volume declines related to manufacturing and packaging services, as well as lower comparator sourcing volume. The nine months FY18 includes a tax charge of $51.6 million as a provisional estimate of the net accounting impact of the recently enacted U.S. tax law changes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters